Hepatitis B vaccine stabilised

Partner: Arecore have been working with the Program for Appropriate Technology in Healthcare (PATH), which is based in Seattle, WA, USA.

This project is part of a program to expand the coverage of hepatitis vaccination in developing countries.

Problem: Vaccines typically rely on a cold-chain of refrigeration to prevent the damage resulting from heat exposure. This limits their availability, particularly in developing countries.

Strategy: Arecor used Arestat™ technology to stabilise recombinant hepatitis B vaccine.

Results:

the vaccine shows stability at temperatures up to 55°C
the integrity of the vaccine has been confirmed by a range of in vitro and in vivo analytical methods.

Last updated: 13 June 2008